Clinical observation of Dachaihu decoction in the treatment of Irascibility hyperactivity syndrome(overabundant liver-fire syndrom) of hypertension

Affiliated Hospital of Shandong University of TCM0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Meet the diagnostic criteria of western medicine for essential hypertension and the diagnostic criteria for the syndrome of dizziness, irascibility and hyperactivity; Hypertension is grade 1, and the risk level is low;
•2. Blood pressure was stable in the past 4 weeks, without the treatment of traditional Chinese medicine or proprietary Chinese medicine, without the treatment of western medicine or western medicine;
•3. Between 18 and 75 years old, gender is not limited;
•4. Patients who volunteer to participate in the trial and sign the informed consent and cooperate with various investigations and tests;
•5. Women of child-bearing age should have a negative pregnancy test and agree to take non-drug contraceptive measures during the test period.

•1. With secondary hypertension, refractory hypertension, malignant hypertension, acute and subacute hypertension, white coat hypertension and unstable blood pressure;
•2. Pregnant and lactating women, women of child-bearing age do not agree to use contraceptive measures during the experiment;
•3. Have mental illness, can't cooperate very well;
•4. The patients with serious heart disease, severe neurosis and heart, liver and kidney dysfunction confirmed by examination;
•5. Severe endocrine, hematopoietic system, liver, kidney and other primary diseases, malignant tumors, mental patients.
•6. With uncorrected hyperthyroidism, hypothyroidism;
•7. Patients with nephrotic syndrome, diabetes mellitus and acute hepatobiliary disease;
•8. People who have suffered from serious cerebrovascular accidents, heart diseases, severe trauma, major surgery and other primary diseases with unstable general conditions and poor prognosis within 6 months.
•9. Cases of Data collected with other disease; Patients who are in the course of drug treatment and affect the investigational drug observer;
•9. Those who have participated in clinical trials of other drugs within three months;
•10. Other conditions that the researchers considered inappropriate for inclusion were eliminated.

发起方

Affiliated Hospital of Shandong University of TCM